Détails

Catégorie : info Réseau 1

Création : 12 juin 2019

Affichages : 1513

NCT03475953

• A Phase II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE)

NCT03780517

• SAFETY, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors

NCT02029001

• MOST: Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: My Own Specific Treatment (MOST plus)

NCT02390934

• RADTHYR: Single arm Phase II trial evaluating the efficacy of Radium 223 in radioactive iodine refractory bone metastases from differentiated thyroid cancer

EudraCT Number: 2017-000742-21

• MERAIODE Efficacy of a selective MEK (trametinib) and BRAFV600E (dabrafenib) inhibitors associated with radioactive iodine (RAI) for the treatment of refractory metastatic differentiated thyroid cancer with RAS or BRAFV600E mutation

NCT02304809

• ACSE Vemurafenib: Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations (AcSé)

NCT02034981

• ACSE Crizotinib: Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1 (AcSé)

NCT03012620

• ACSE Pembrolizumab: Secured Access to Pembrolizumab for Adult Patients With Selected Rare Cancer Types (AcSé)

NCT03157128

• LIBRETTO 001: Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer

NCT03037385

• Phase 1 Study of the Highly-selective RET Inhibitor BLU-667 in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

NCT01945762

• European, Observational, Prospective Study to Evaluate the Benefit/Risk of Vandetanib (CAPRELSA™) 300 mg in RET Mutation Negative and RET Mutation Positive Patients with Symptomatic, Aggressive, Sporadic, Unresectable, Locally Advanced/Metastatic Medullary Thyroid Cancer (MTC).

NCT02702388

• A Multicenter, Randomized, Double-Blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will Provide Comparable Efficacy to a 24-mg Starting Dose, But Have a Better Safety Profile

NCT01896479

• EXAMINER: A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients

NCT02568267

• An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements